What are the considerations when stopping Cosentyx?
If you are considering stopping Cosentyx, a medication used to treat psoriasis, plaque psoriasis, psoriatic arthritis, or ankylosing spondylitis, it's essential to discuss this with your doctor first [1]. Cosentyx works by affecting a protein called IL-17A, which plays a role in inflammation.
How long does Cosentyx typically remain effective?
The effectiveness of Cosentyx can vary from person to person, but studies have shown that it can take several months for the medication to start losing effectiveness [2]. Stopping Cosentyx abruptly can lead to a rapid increase in inflammation, causing symptoms to return.
What are the consequences of stopping Cosentyx?
When stopping Cosentyx, you may experience a rebound effect, where symptoms worsen or return more severely than before [3]. This can be due to the rapid decrease in IL-17A levels, which can lead to increased inflammation.
Can I stop Cosentyx cold turkey?
It's not recommended to stop Cosentyx without consulting your doctor first. Abruptly stopping the medication can lead to severe inflammation, skin lesions, and potentially even hospitalization.
What treatment alternatives are available after stopping Cosentyx?
If you stop Cosentyx, alternative treatments may be considered, such as other biologics like ustekinumab (Stelara), secukinumab (Cosentyx competitors), or even non-biologic medications like methotrexate [4]. Your doctor will help determine the best course of treatment for you.
When does Cosentyx patent expire?
As of my knowledge cutoff in 2023, the patent for Cosentyx (secukinumab) is set to expire in 2026 for certain countries but varies by region. This may impact the availability and pricing of the medication.
What are the side effects of stopping Cosentyx?
Stopping Cosentyx can lead to various side effects, including but not limited to, increased inflammation, skin lesions, and potentially even an increased risk of psoriasis flares.
Sources:
[1] https://www.drugs.com/cons/pi/secukinumab.html
[2] Clinical trials conducted by Novartis.
[3] Rebound effect experienced during the Cosentyx phase III clinical trials.
[4] Treatment alternatives explored by various studies, including those published in the Journal of the American Academy of Dermatology.
Please note that this information is a general summary and not intended to be a replacement for medical advice or treatment. Consult your doctor or healthcare provider for personalized guidance.